EX-10.58 2 d231890dex1058.htm EXCLUSIVE CLINICAL STUDY AND DATA LICENSE AGREEMENT [*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ****,...Exclusive Clinical Study and Data License Agreement • May 5th, 2020 • Delaware
THIS EXCLUSIVE CLINICAL STUDY AND DATA LICENSE AGREEMENT (the “Agreement”) is made as of June 12, 2009 (the “Effective Date”) between VIROPHARMA INCORPORATED, a Delaware corporation (“ViroPharma”), and GENZYME CORPORATION, a Massachusetts corporation (“Genzyme”).
AMENDMENT NO. 2 TO EXCLUSIVE CLINICAL STUDY AND DATA LICENSE AGREEMENT BETWEEN GENZYME CORPORATION AND VIROPHARMA INCORPORATEDExclusive Clinical Study and Data License Agreement • February 28th, 2012 • Viropharma Inc • Pharmaceutical preparations
This Amendment No. 2 (the “Amendment”) to the Exclusive Clinical Study and Data License Agreement dated June 12, 2009 (the “Agreement”) by and between Genzyme Corporation (“Genzyme”) and ViroPharma Incorporated (“ViroPharma”), as amended on October 21, 2009, is effective as of April 5, 2010 (“Amendment Effective Date”).
AMENDMENT NO. 1 TO EXCLUSIVE CLINICAL STUDY AND DATA LICENSE AGREEMENT BETWEEN GENZYME CORPORATION AND VIROPHARMA INCORPORATEDExclusive Clinical Study and Data License Agreement • February 28th, 2012 • Viropharma Inc • Pharmaceutical preparations
This Amendment No. 1 (the “Amendment”) to the Exclusive Clinical Study and Data License Agreement dated June 12, 2009 (the “Agreement”) by and between Genzyme Corporation (“Genzyme”) and ViroPharma Incorporated (“ViroPharma”), is effective as of October 22, 2009 (“Amendment Effective Date”).
